Patents Assigned to The Translational Genomics Research Institute
  • Targeted therapies for cancer
    Patent number: 9750741
    Abstract: Methods of selecting a chemotherapy regimen for treatment of cancer in a patient are disclosed. A patient genetic sample from a bilary cancer such as cholangiocarcinoma is analyzed for a mutation in ERRFI1 and a chemotherapeutic agent is selected as a result of the analysis. If a mutation in ERRFI1 is present, treatment with an inhibitor of Epidermal Growth Factor Receptor (EGFR) is shown to have inhibitory effects on tumor growth. In this manner, the chemotherapy regimen is targeted to a given mutation in a patient's cancer.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: September 5, 2017
    Assignees: The Translational Genomics Research Institute, MAYO Foundation for Medical Education and Research
    Inventors: Mitesh Jivraj Borad, David Craig, John Carpten
  • Systems and methods for diagnosing and treating cancer
    Patent number: 9745634
    Abstract: This invention identifies and provides a recurrent translocation t(4;8) (p16.2; p23.1) associated with certain cancers and other abnormal cell growth disorders and diagnostic methods using the translocation by FISH hybridization or PCR based assays.
    Type: Grant
    Filed: November 20, 2014
    Date of Patent: August 29, 2017
    Assignee: The Translational Genomics Research Institute
    Inventors: Kimberly Bussey, Michael J. Demeure
  • Hybridoma clones, monoclonal antibodies, and methods of use
    Patent number: 9738717
    Abstract: The present invention is directed to a monoclonal antibody that recognizes human CD63 in its native form. The invention is also directed to a hybridoma cell line that produces the monoclonal antibody, and to methods of diagnosing and treating cancer and purifying exosomes using the antibody. The invention is further directed to pharmaceutical compositions comprising an antibody of the invention and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: May 15, 2013
    Date of Patent: August 22, 2017
    Assignee: The Translational Genomics Research Institute
    Inventor: David Azorsa
  • GENETIC SIGNATURE OF VULNERABILITY TO INHIBITORS OF BASE EXCISION REPAIR (BER) IN CANCER
    Publication number: 20170204472
    Abstract: The invention relates to the identification of genetic signatures and expression profiles that are a part of the Base Excision Repair (BER) pathway, a major DNA repair pathway that modifies base lesions. In one embodiment, the present invention provides a method of determining responsiveness of treatment by BER inhibitors for malignant glioma by determining the presence of a low level of expression of Apex 1, a low level of expression of Apex 2, and a high level of expression of MPG.
    Type: Application
    Filed: March 31, 2017
    Publication date: July 20, 2017
    Applicants: Dignity Health, The Translational Genomics Research Institute
    Inventors: Shwetal V. Mehta, Michael E. Berens, Harshil Dineshkumar Dhruv
  • CANINE AUTOIMMUNE CONDITIONS AND DIAGNOSIS AND TREATMENT THEREOF
    Publication number: 20170166964
    Abstract: The disclosure includes methods of identifying a dog at risk of developing a an autoimmune disease or condition, for example a hypothyroid disease or condition, comprising testing whether the dog exhibits one or more selected single nucleotide polymorphisms (SNPs), together with diagnostic kits for carrying out such methods, methods of treatment or prophylaxis of such autoimmune disease or condition, e.g., comprising administering an effective amount of tea extract to a dog in need thereof, and a canine diet or supplement comprising tea extract, useful for treatment of prophylaxis of such autoimmune disease or condition, or for maintenance of thyroid health in a dog.
    Type: Application
    Filed: November 25, 2013
    Publication date: June 15, 2017
    Applicants: HILL'S PET NUTRITION, INC., THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE
    Inventors: Jeffrey BROCKMAN, Matthew J. HUENTELMAN
  • System and method of genomic profiling
    Patent number: 9663826
    Abstract: The present invention relates to a system and method of genomic profiling and is particularly useful in genomic differentiation of heterogeneous and polyclonal neoplastic cell populations, preferably of flow sorted formalin fixed paraffin embedded samples. The present invention includes methods of improving resolution for identifying aberration in variable carcinoma genomes and/or heterogeneous cell populations. The present invention also includes kits configured to improve genomic resolution and the ability to identify genomic aberration in variable and/or heterogeneous cell populations.
    Type: Grant
    Filed: February 15, 2013
    Date of Patent: May 30, 2017
    Assignee: The Translational Genomics Research Institute
    Inventors: Michael T. Barrett, Elizabeth Lenkiewicz, Tara Holley
  • Genetic signature of vulnerability to inhibitors of base excision repair (BER) in cancer
    Patent number: 9637798
    Abstract: The invention relates to the identification of genetic signatures and expression profiles that are a part of the Base Excision Repair (BER) pathway, a major DNA repair pathway that modifies base lesions. In one embodiment, the present invention provides a method of determining responsiveness of treatment by BER inhibitors for malignant glioma by determining the presence of a low level of expression of Apex 1, a low level of expression of Apex 2, and a high level of expression of MPG.
    Type: Grant
    Filed: May 21, 2014
    Date of Patent: May 2, 2017
    Assignees: Dignity Health, The Translational Genomics Research Institute
    Inventors: Shwetal V. Mehta, Michael E. Berens, Harshil Dineshkumar Dhruv
  • Compounds for cognitive enhancement and methods of use thereof
    Patent number: 9617214
    Abstract: The invention provides compounds that inhibit ROCK activity. In certain embodiments the compounds of the invention enhance cognitive function. The invention is also directed to pharmaceutical compositions that comprise ROCK inhibitors and to methods enhance cognitive function and reducing and/or treat cognitive function decline.
    Type: Grant
    Filed: November 10, 2014
    Date of Patent: April 11, 2017
    Assignee: The Translational Genomics Research Institute
    Inventors: Tong Wang, Travis Dunckley, Matthew Huentelman
  • Hybridoma clones and monoclonal antibodies to fibroblast growth factor 4
    Patent number: 9611319
    Abstract: The present invention is directed to a monoclonal antibody that recognizes human FGFR4 in its native form. The invention is also directed to a hybridoma cell line that produces the monoclonal antibody and methods of use thereof.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: April 4, 2017
    Assignee: The Translational Genomics Research Institute
    Inventor: David Azorsa
  • Methods of identifying and treating glioblastoma
    Patent number: 9587239
    Abstract: The invention encompasses methods and kits used in the detection of invasive glioblastoma based upon the expression of NHERF-1. The methods and kits also allow prediction of disease outcome as well as therapeutic outcome.
    Type: Grant
    Filed: February 23, 2015
    Date of Patent: March 7, 2017
    Assignee: The Translational Genomics Research Institute
    Inventors: Kerri L. Kislin, Michael Edward Berens
  • METHODS AND KITS TO IDENTIFY KLEBSIELLA STRAINS
    Publication number: 20170022543
    Abstract: Embodiments of the invention provide a method of detecting one or more strains of Klebsiella pneumoniae. The method may include forming a plurality of mixtures for nucleic amplification. The method can include amplification of specific sequences within the K. pneumonia genome that can provide definitive information to distinguish between one or more types or strains of K. pneumonia.
    Type: Application
    Filed: July 20, 2016
    Publication date: January 26, 2017
    Applicants: THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE, ARIZONA BOARD OF REGENTS ON BEHALF OF NORTHERN ARIZONA UNIVERSITY
    Inventors: Jolene Bowers, Elizabeth Driebe, David Engelthaler, Paul Keim
  • METHODS USED TO TREAT CANCER
    Publication number: 20170009231
    Abstract: The invention encompasses methods used in the sensitization and treatment of cancer based upon the expression of SGEF.
    Type: Application
    Filed: July 7, 2016
    Publication date: January 12, 2017
    Applicant: THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE
    Inventor: NHAN TRAN
  • Therapeutic combination for cancer treatment
    Patent number: 9532984
    Abstract: This invention relates to a synergistic pharmaceutical combination of glucose lowering drugs and autophagy inhibitors, kits containing such combinations, and methods of using such combinations to treat subjects suffering from cancers carrying a specific KRAS mutation. This invention also relates to a theranostic method for cancer treatment.
    Type: Grant
    Filed: June 11, 2012
    Date of Patent: January 3, 2017
    Assignee: The Translational Genomics Research Institute
    Inventor: Stephen T. Gately
  • METHODS AND KITS TO PREDICT THERAPEUTIC OUTCOME OF BTK INHIBITORS
    Publication number: 20160346285
    Abstract: Methods of tests that assess the expression of DPC4 (SMAD4) to identify subjects with pancreatic cancer that are likely or unlikely to respond to treatment with BTK inhibitors; methods of treating subjects based on identification of the subjects as likely to respond to treatment with BTK inhibitors; therapeutic targets for cancers, particularly cancers with inactivated DPC4 gene or protein; methods of screening of new therapeutic agents using the target; pharmaceutical composition comprising BTK inhibitors, such as PCI-32765 or derivatives thereof, for cancer treatment; and kits that facilitate the performance of the methods are disclosed.
    Type: Application
    Filed: June 20, 2016
    Publication date: December 1, 2016
    Applicant: THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE
    Inventors: Haiyong HAN, Daniel VON HOFF, Caroline H. DIEP, Hongwei YIN
  • Method of Identifying Tyrosine Kinase Receptor Rearrangements in Patients
    Publication number: 20160340742
    Abstract: The present invention provides a method of characterizing a cancer by obtaining a sample from a subject suspected of having cancer; and determining whether a fibroblast growth factor receptor (FGFR) fusion is present in the sample, wherein the FGFR fusion comprises a FGFR locus, thereby characterizing the cancer based on the presence or absence of the FGFR fusion.
    Type: Application
    Filed: February 4, 2015
    Publication date: November 24, 2016
    Applicants: Mayo Foundation for Medical Education and Research, Translational Genomics Research Institute
    Inventors: Rondell P. Graham, Mitesh J. Borad, Benjamin R. Kipp, Emily G. Barr Fritcher, John Carpten, David Craig
  • METHOD OF DETECTING COCCIDIOIDES SPECIES
    Publication number: 20160326603
    Abstract: The present technology provides methods and kits that may be used to detect and quantify the presence of Coccidioides species. The methods include quantification real-time PCR assays, and the kits and compositions include oligonucleotides used as primers and probes.
    Type: Application
    Filed: July 29, 2016
    Publication date: November 10, 2016
    Applicants: THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE, ARIZONA BOARD OF REGENTS ON BEHALF OF NORTHERN ARIZONA UNIVERSITY
    Inventors: Bridget Barker, Elizabeth Driebe, David Engelthaler, Paul Keim, Jolene Bowers
  • Benzamide derivatives
    Patent number: 9464059
    Abstract: Disclosed are benzamide derivatives having the formula wherein X is selected from the group consisting of H, halo, —C1-C6 alkyl, aryl, —C3-C7 cycloalkyl, and -3- to 10-membered heterocycle, wherein the —C1-C6 alkyl, aryl, —C3-C7 cycloalkyl, and -3- to 10-membered heterocycle may be unsubstituted or substituted; Y is selected from the group consisting of H, —C1-C6 alkyl, and —C3-C7 cycloalkyl, the —C1-C6 alkyl, aryl, —C3-C7 cycloalkyl, and -3- to 10-membered heterocycle may be unsubstituted or substituted; Z is selected from the group consisting of —NHOH and phenylene diamine group (II) of structure and wherein Q is selected from the group consisting of H, F and Cl. These benzamide derivatives are useful in slowing the expansion of cancer cells.
    Type: Grant
    Filed: June 8, 2015
    Date of Patent: October 11, 2016
    Assignee: The Translational Genomics Research Institute
    Inventors: Tong Wang, Stephen Gately
  • COMPOUNDS FOR COGNITIVE ENHANCEMENT AND METHODS OF USE THEREOF
    Publication number: 20160272587
    Abstract: The invention provides compounds that inhibit ROCK activity. In certain embodiments the compounds of the invention enhance cognitive function. The invention is also directed to pharmaceutical compositions that comprise ROCK inhibitors and to methods enhance cognitive function and reducing and/or treat cognitive function decline.
    Type: Application
    Filed: November 10, 2014
    Publication date: September 22, 2016
    Applicants: The Translational Genomics Research Institute, Translational Drug Development, LLC
    Inventors: Tong Wang, Travis Dunckley, Matthew Huentelman
  • Solid forms of curcumin
    Patent number: 9447050
    Abstract: The present invention provides forms of curcumin and the pharmaceutical compositions thereof. The forms of curcumin disclosed herein are curcumin polymorph Form III, curcumin-2-aminobenzimidazole co-crystal, and curcumin-L-lysine co-crystal. Further, the invention provides methods inhibiting cancer cells and HSV-1 using these curcumin novel solid forms.
    Type: Grant
    Filed: April 5, 2012
    Date of Patent: September 20, 2016
    Assignees: THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE, VAN ANDEL RESEARCH INSTITUTE
    Inventors: Stephen T. Gately, Steven J. Triezenberg, Tong Wang
  • Methods and kits used in the detection of fungus
    Patent number: 9434986
    Abstract: The invention encompasses method of using quantitative PCR to detect fungal organisms in clinical and environmental samples to generate standards that allow the quantification of fungal organisms in the samples.
    Type: Grant
    Filed: May 12, 2014
    Date of Patent: September 6, 2016
    Assignees: THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE, ARIZONA BOARD OF REGENTS ON BEHALF OF NORTHERN ARIZONA UNIVERSITY
    Inventors: Cindy Liu, Sergey Kachur, Lance Price, Paul Keim